Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Evolent Health. The associated price target remains the same with $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Charles Rhyee has given his Buy rating due to a combination of factors that indicate a positive outlook for Evolent Health. The company is expected to report a strong second quarter, driven by favorable trends in oncology that could lead to an increase in their 2025 adjusted EBITDA guidance. This optimism is supported by management’s potential to raise their guidance by $5 million, reflecting confidence in ongoing business performance.
Additionally, Evolent Health has shown promising pipeline growth, with new business opportunities emerging from both existing and new clients. While the majority of these contributions are anticipated in 2026, some impact could be realized as early as the second quarter, which would be positively received by investors. Despite potential challenges from Medicaid work requirements, the overall outlook remains strong, justifying the Buy rating.
Rhyee covers the Healthcare sector, focusing on stocks such as CVS Health, Evolent Health, and Teladoc. According to TipRanks, Rhyee has an average return of 1.6% and a 47.50% success rate on recommended stocks.
In another report released on July 7, Truist Financial also reiterated a Buy rating on the stock with a $14.00 price target.